The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
More news re MABS, can only be good for Foralumab and it’s administration
https://www.reuters.com/article/us-health-coronavirus-europe-antibody-idUKKBN2AX1YT
As posted in stocktwits: $1.9b buy-out for bemarituzumab
https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal
With the potential in Foralumba not just for Covid, the future is bright in my eyes
Been weeks now of doomsday messages and people demanding Accustem.
Are the board historically not great at keeping time frames, yes. But also factor in that during normal times they probably would have hit the time frames. Pandemic is causing delays. KS recently just said all work their side is done and now it is out of their hands.
On other fronts, treatments, tech, innovation, trials they have delivered. Fundamentals stronger than 12 months ago. Accustem will come. Guess people wanted a quick flip. But at 40% superiority to market leader, its worth the wait.
I will be holding for years or a buy out.
Supposedly by end of Q1, so hopefully listed by end of Month
It’s tomorrow 24th
DaveyCR
He’s merely quoting someone off stocktwits with a bit of optimism looking into next week. As per your tweet “please provide the name of the person and they will be reported”, I mean....
Far far worse rampers on here and more so de-rampers on here.
Especially those that I have noticed recently creating new threads at any given opportunity with negative sentiment/connotations attached.
Not a great week for this board IMO with everyone ready to attack each other. GLA next week, enjoy the weekend and here’s to a favourable RNS.
Axe,
The updated presentation showed data to be available by January.
https://ir.tizianalifesciences.com/static-files/1341c6cf-c175-4161-b0b4-0a9c7471790b
Mentioned in multiple interviews and 4th January RNS.
Initially results were expected December then pushed back to January.
I’m expecting RNS next week. Tomorrow would be quite nice too
Davey,
100% agree.
Under promise, over deliver, create a history of this and that way will help sentiment and potentially help stop shorters. As they could get caught out any time based on a history of over promising/delivering.
Right now it’s constant missing of deadlines. In fact with the last 6-8 months history of it, it helps those too short.
BMO3
The Dr needs to learn to stick to dates and timelines that have been mentioned in interviews and states in RNS’s.
We went through this same issue Q3/Q4 2020 where all dates were missed. This industry & current world events delays are inevitable. However do not mention dates unless you know they can be met.
Results were due December, then January and now it seems they will come in feb?!?!? It’s like everytime a date is mentioned shorters jump in as they know a slip will occur.
PR machine would have been better starting up mid jan or closer to actually results. As I feel all good news has been neutralised due to shorting and pullback.
GLA, I’m in her for the LTH seen this hit 2.50+ and it will get there and more again.
I think it’s mad how we are still at these levels with news, PR, Pipeline, Funding and more.
Something still holding us down? Purchaser of Emperys shares? Any ideas welcome
You can see they now hold 0 shares here:
https://fintel.io/so/uk/tils
That would explain the selling and NAS BOT prior to the new year.
TR-1 must be released shortly im assuming to whoever hovered them up. GLA
You’ll find the article is just a copy and paste of the below by SeekingAlpha, with the added “I/We are short ......” morons
https://seekingalpha.com/article/4400769-cytodyn-and-humanigen-ticking-time-bombs-impending-results-likely-to-fail
No mention of TILS or TLSA. So just a shorts agenda. Just like the Tom W article months back.
IMO
As per 4th January RNS:
“ The topline data from the trial is expected to be available in January 2021”
Again, they should not state dates they cannot hit. Should have learnt from this. Now on main market they need to act in a more timely manner. But we still have 4 more working business days in January, so let’s see.
Drop due to the delay in results I expect. Initially they were expected in December, then early Jan, then EOM and now potentially within two weeks. Normal TILS behaviour in over promising on timelines. In future I’d like to see them under promise and over deliver. All in my opinion.
Yesterday’s conference call now available
https://www.webcaster4.com/Webcast/Page/2433/39713
Last stop/loss hunt before the move / news going on right now I think...
0161
Agree with your views.
Mentioned a while back if for some reason a company or institution was purposely tying to keep price low in order to make an offer based off of 6-12 month price once move to main market has occurred.
Could come to fruition seeing the moves on OKYO and ACCU boards. Plus Accustem being personal to GC.
Over a million£ in fact delayed reported trades.
Exciting 7 days ahead
Must be good news re Foralumab. Brought on board to speed up next phase???